HIV/AIDS News and Research RSS Feed - HIV/AIDS News and Research Twitter

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV).

This condition progressively reduces the effectiveness of the immune system and leaves individuals susceptible to opportunistic infections and tumors. HIV is transmitted through direct contact of a mucous membrane or the bloodstream with a bodily fluid containing HIV, such as blood, semen, vaginal fluid, preseminal fluid, and breast milk.
Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets. [More]
NYUCD receives NIH grant to develop POC test to detect HIV antibodies and viral RNA

NYUCD receives NIH grant to develop POC test to detect HIV antibodies and viral RNA

New York University College of Dentistry has received a sub-award in the amount of $335,000 from a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health to complete the development of a fully automated self-confirming assay that can simultaneously detect HIV/AIDS antibodies and viral RNA from the AIDS virus in a single specimen. [More]
TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and impact of child and maternal health programs around the world to include the diagnosis and treatment of pediatric tuberculosis (TB), a significant cause of child mortality. [More]
APM, HIV/AIDS Resource Center merge to strengthen response to HIV in Southeast Michigan

APM, HIV/AIDS Resource Center merge to strengthen response to HIV in Southeast Michigan

In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside. [More]
Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO). [More]
Janssen announces acquisition of XO1

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. [More]
MGH study suggests that bariatric surgery can reduce risk of asthma attacks

MGH study suggests that bariatric surgery can reduce risk of asthma attacks

A study led by Massachusetts General Hospital investigators suggests that bariatric surgery can significantly reduce the risk of asthma attacks - also called exacerbations - in obese patients with asthma. [More]
GHTC report confronts key challenge of renewing US leadership in global health technology

GHTC report confronts key challenge of renewing US leadership in global health technology

‚ÄčToday, the world is looking to the United States for cutting-edge diagnostics, drugs, and vaccines that could have the last word on an Ebola outbreak that is down but not out. But those innovations are the product of past US investments in research and development (R&D). [More]
Brazil's first open-access research facility to be established at UNICAMP

Brazil's first open-access research facility to be established at UNICAMP

Open-access research into drug discovery has arrived in South America, with a ground-breaking collaboration between leading scientists in North America, Europe and Brazil to provide completely free and open research results to the world. [More]

Mylan releases Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr in U.S.

Mylan N.V. and Mylan Inc. today announced the U.S. launch of its Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr, adding to its existing offering of Fentanyl Transdermal System 12, 25, 50, 75 and 100 mcg/hr. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
Simple low-cost intervention could help reduce HIV-related deaths in Africa

Simple low-cost intervention could help reduce HIV-related deaths in Africa

A new approach to care for patients with advanced HIV in Tanzania and Zambia, combining community support and screening for a type of meningitis, has reduced deaths by 28%. [More]
Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. [More]
Lifestyle intervention program at workplace reduces risk factors for diabetes, heart disease

Lifestyle intervention program at workplace reduces risk factors for diabetes, heart disease

A healthy lifestyle intervention program administered at the workplace and developed by the University of Pittsburgh Graduate School of Public Health significantly reduces risk factors for diabetes and heart disease, according to a study reported in the March issue of the Journal of Occupational and Environmental Medicine. [More]
Women for Positive Action introduces new educational tool for women living with HIV

Women for Positive Action introduces new educational tool for women living with HIV

To mark International Women's Day (March 8, 2015), Women for Positive Action has launched a practical and informative new educational tool entitled 'Hepatitis and coinfection in women living with HIV'. Led by a global, multidisciplinary group of experts, Women for Positive Action is committed to addressing the specific concerns of women living with HIV. [More]
WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355). [More]

Mylan acquires non-U.S. developed markets specialty and branded generics business from Abbott

Mylan N.V. and Mylan Inc. today announced the successful completion of the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business. [More]
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

The Medicines Patent Pool announced a licence today with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children living with HIV four weeks of age and older. [More]
Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. [More]
Advertisement
Advertisement